Department of Oncology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Department of Endocrinology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Int J Mol Sci. 2022 Sep 16;23(18):10823. doi: 10.3390/ijms231810823.
Malignant tumors are always a critical threat to human health, with complex pathogenesis, numerous causative factors, and poor prognosis. The features of cancers, such as gene mutations, epigenetic alterations, and the activation and inhibition of signaling pathways in the organism, play important roles in tumorigenesis and prognosis. MicroRNA (miRNA) enables the control of various molecular mechanisms and plays a variety of roles in human cancers, such as radiation sensitivity and tumor immunity, through the regulation of target genes. MiR-149-5p participates in the process and is closely related to lipogenesis, the migration of vascular endothelial cells, and the expression of stem-cell-related proteins. In recent years, its role in cancer has dramatically increased. In this review, we summarize the regular physiological roles of miRNAs, specifically miR-149-5p, in the organism and discuss the tumor-suppressive or oncogenic roles of miR-149-5p in different human cancers with respect to signaling pathways involved in regulation. Possible clinical applications of miR-149-5p in future targeted therapies and prognosis improvement in oncology are suggested.
恶性肿瘤一直是对人类健康的重大威胁,具有复杂的发病机制、众多的致病因素和较差的预后。癌症的特征,如基因突变、表观遗传改变和机体信号通路的激活和抑制,在肿瘤发生和预后中发挥重要作用。MicroRNA(miRNA)通过调节靶基因,使各种分子机制得到控制,并在人类癌症中发挥多种作用,如辐射敏感性和肿瘤免疫。miR-149-5p 参与其中,与脂肪生成、血管内皮细胞迁移和干细胞相关蛋白的表达密切相关。近年来,它在癌症中的作用显著增加。在这篇综述中,我们总结了 miRNA,特别是 miR-149-5p,在机体中的正常生理作用,并讨论了 miR-149-5p 在不同人类癌症中通过参与调节的信号通路的抑癌或致癌作用。还提出了 miR-149-5p 在未来肿瘤学靶向治疗和预后改善中的可能临床应用。
Int J Mol Sci. 2022-9-16
FEBS Open Bio. 2020-4
Int J Mol Sci. 2021-12-30
Biomed Pharmacother. 2022-2
Transl Oncol. 2025-2
Medicine (Baltimore). 2024-2-23
Am J Cancer Res. 2023-12-15
Front Oncol. 2023-6-19
Int J Mol Sci. 2023-5-12
Biomed Res Int. 2022
Int J Mol Sci. 2022-7-8
J Healthc Eng. 2022